The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 ...

The results shed light on how MariTide may measure up to weight loss injections from Novo Nordisk and Eli Lilly and other ...

Shares in Amgen fell on Tuesday after they announced the results of a trial for their weight loss drug MariTide.

Shares in Amgen fell by double digits Tuesday on results for the company’s MariTide shot, which is viewed as a potential ...

Amgen's experimental drug MariTide helped overweight or obese patients lose up to 20% weight on average in a year-long ...

An Amgen obesity drug helped participants lose a substantial amount of weight, but questions about how competitive it could ...

A new weight loss drug called MariTide caused 20 percent weight loss in a recent trial, even better than Wegovy or Ozempic.

MariTide, which like Eli Lilly’s Zepound is a dual agonist of the GLP-1 and GIP receptors, demonstrated an average weight ...

Amgen's experimental drug MariTide led to an average weight loss of up to 20% in a year-long mid-stage trial of nearly 600 ...

Amgen (AMGN) fell sharply during Tuesday's intraday trading following the release of phase two trial results for its monthly ...

Data from a phase II study shows that AMGN's obesity drug MariTide leads to sustainable weight loss, robust improvements in ...